Consistent with these findings, we found that NG25, a synthesized TAK1 inhibitor, could sensitize the breast cancer cells to Dox mediated cytotoxicity through inhibiting the activation of NF-κB pathway. The gene discussed is NFKB1; the disease is breast carcinoma.